Tdam USA Inc. reduced its position in Novo Nordisk A/S (NYSE:NVO) by 18.1% during the second quarter, Holdings Channel reports. The institutional investor owned 14,464 shares of the company’s stock after selling 3,201 shares during the period. Tdam USA Inc.’s holdings in Novo Nordisk A/S were worth $613,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Proficio Capital Partners LLC increased its stake in Novo Nordisk A/S by 155.6% in the first quarter. Proficio Capital Partners LLC now owns 2,472 shares of the company’s stock worth $103,000 after buying an additional 1,505 shares during the last quarter. Parallel Advisors LLC increased its stake in Novo Nordisk A/S by 120.3% in the first quarter. Parallel Advisors LLC now owns 2,844 shares of the company’s stock worth $117,000 after buying an additional 1,553 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Novo Nordisk A/S by 167.8% in the first quarter. Tower Research Capital LLC TRC now owns 3,061 shares of the company’s stock worth $105,000 after buying an additional 1,918 shares during the last quarter. Cornerstone Advisors Inc. increased its stake in Novo Nordisk A/S by 1,220.2% in the second quarter. Cornerstone Advisors Inc. now owns 3,525 shares of the company’s stock worth $151,000 after buying an additional 3,258 shares during the last quarter. Finally, Advisory Services Network LLC purchased a new stake in Novo Nordisk A/S during the first quarter worth $127,000. 6.40% of the stock is currently owned by institutional investors.

Shares of Novo Nordisk A/S (NYSE NVO) opened at 44.57 on Thursday. The company has a market cap of $111.24 billion, a P/E ratio of 18.33 and a beta of 0.63. Novo Nordisk A/S has a 12-month low of $30.89 and a 12-month high of $47.98. The company has a 50-day moving average price of $42.68 and a 200-day moving average price of $38.69.

WARNING: This report was originally reported by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.dailypolitical.com/2017/08/10/novo-nordisk-as-nysenvo-stake-cut-by-tdam-usa-inc.html.

NVO has been the subject of a number of recent research reports. Zacks Investment Research downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. BidaskClub downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. Finally, TheStreet upgraded Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research report on Tuesday, May 2nd. Five investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $53.00.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.